|Printable version||E-mail this to a friend|
How big data can be used for the development and regulation of medicines
EMA workshop broadcast live on 14-15 November
The European Medicines Agency (EMA) is organising a workshop on 14-15 November 2016 to identify opportunities for big data in medicines development and regulation, and to address the challenges of their exploitation. You can follow a live broadcast of the workshop by clicking on the ‘multimedia’ tab on the event page.
Big data is a term which describes the collection of extremely large sets of information which require specialised computational tools to enable their analysis and exploitation. These vast volumes of data have the capability to significantly contribute to the way the benefit-risk of medicines is assessed over the entire lifecycle. A subset of big data is real world evidence, which encompasses the use of sources such as electronic health records, registries, hospital records and health insurance data. Already used to support pharmacovigilance activities, real world evidence has the potential to support product development and the assessment of performance of a medicine on the market.
While creating huge opportunities, there are also significant challenges in the exploitation of these data. For example there is a need to establish appropriate access to the data, to understand the strengths and limitations of the data and to apply new analytical methods to integrate and analyse heterogeneous datasets in order to generate conclusions which contribute to regulatory decision making. Importantly, compliance with data protection legislation ensuring robust mechanisms to protect patient confidentiality is critical for securing patient trust.
The workshop will bring together a wide range of individuals from the healthcare environment and technology companies, who can inform on the advances being made in the field of big data and the opportunities for its application in medicine regulation. This landscaping exercise will help regulators to determine the best approaches to using big data for the development, authorisation and post-marketing surveillance of medicines.
More details on this workshop’s sessions and speakers are provided in the agenda for the meeting.
Individuals interested in tweeting on this event are invited to use the hashtag #bigdata4medicines.
- Identifying opportunities for ‘big data’ in medicines development and regulatory science (14-15/11/2016)
- Agenda - Identifying opportunities for 'big data' in medicines development and regulatory science (08/11/2016)
Latest News from
Parliament demands better protection for small investors03/12/2016 10:15:00
Small investors need better information about the possible risks & fees for investment products they might buy, say MEPs.
Simpler website navigation for regulatory information on human medicines03/12/2016 08:15:00
The European Medicines Agency (EMA) has simplified the navigation structure of the regulatory information on human medicines on its website, to help users from pharmaceutical companies find the information they need more quickly and easily.
EU and Germany reach agreement on a fair and non-discriminatory road charging scheme02/12/2016 16:27:00
After years of discussions between the EC and the German authorities, both parties agreed on a solution to put an end to the legal dispute over the planned introduction of a road charge for passenger cars in Germany.
European fund for sustainable development: Council agrees negotiating position02/12/2016 16:10:00
On 1 December 2016, the Permanent Representatives Committee (Coreper) agreed on the Council's negotiating position on the regulation on the European fund for sustainable development (EFSD) and establishing the EFSD guarantee and the EFSD guarantee fund. The text will be presented for adoption to the Council in December 2016.
‘Avalanche’ network dismantled in international cyber operation02/12/2016 15:37:00
After more than four years of investigation, the Public Prosecutor’s Office Verden and the Lüneburg Police (Germany), in close cooperation with the United States Attorney’s Office for the Western District of Pennsylvania, the Department of Justice and the FBI, Eurojust, Europol and global partners, dismantled an international criminal infrastructure platform known as ‘Avalanche’.